Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Immunol. 2012 Nov 30;190(1):447–457. doi: 10.4049/jimmunol.1201641

FIGURE 3. GVHD and GVL potential of B10.BR CD8+Vβ13+ donor T cells in MMC6-challenged CBA recipients.

FIGURE 3

A and B, CBA mice were exposed to lethal irradiation (11 Gy, split dose) and transplanted with 2×106 ATBM cells alone or along with either unseparated CD8+ T cells (1×107) or CD8+Vβ13+ T cells (1x, 8.34×105; 2x, 1.67×106; or 3x, 2.5×106) from B10.BR donor mice. A, Statistical significance between survival curves was determined using the non-parametric Wilcoxon test. ATBM + CD8+ T cells versus ATBM + CD8+Vβ13+ T cells (1x), p < 0.02; ATBM + CD8+ T cells versus ATBM + CD8+Vβ13+ T cells (3x), p = 0.9. B, All groups except ATBM alone were challenged with MMC6 tumor cells (5×103) on d 1 post-BMT. Experiments were repeated twice with 3-5 mice per group. ATBM + MMC6 versus ATBM + MMC6 + CD8+Vβ13+ T cells (1x), p < 0.01; ATBM + MMC6 versus ATBM + MMC6 + CD8+Vβ13+ T cells (2x), p < 0.01; ATBM + MMC6 versus ATBM + MMC6 + CD8+Vβ13+ T cells (3x), p < 0.01; ATBM + MMC6 + CD8+Vβ13+ T cells (1x) versus ATBM + MMC6 + CD8+Vβ13+ T cells (2x), p = 0.59; ATBM + MMC6 + CD8+Vβ13+ T cells (1x) versus ATBM + MMC6 + CD8+Vβ13+ T cells (3x), p = 0.05; ATBM + MMC6 + CD8+Vβ13+ T cells (2x) versus ATBM + MMC6 + CD8+Vβ13+ T cells (3x), p < 0.02.